Deferred Tax Assets, Valuation Allowance of Vaxcyte, Inc. from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Vaxcyte, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
  • Vaxcyte, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $645,313,000, a 45% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Vaxcyte, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $645,313,000 +$199,215,000 +45% 31 Dec 2025 10-K 24 Feb 2026 2025 FY
Q4 2024 $446,098,000 +$157,933,000 +55% 31 Dec 2024 10-K 24 Feb 2026 2025 FY
Q4 2023 $288,165,000 +$123,732,000 +75% 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q4 2022 $164,433,000 +$67,848,000 +70% 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q4 2021 $96,585,000 +$32,964,000 +52% 31 Dec 2021 10-K 27 Feb 2023 2022 FY
Q4 2020 $63,621,000 +$35,450,000 +126% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q4 2019 $28,171,000 31 Dec 2019 10-K 29 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.